Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 101

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Cytochromes P450: Roles in Diseases

Pikuleva, Irina A., Waterman, Michael R.·2013·Journal of Biological Chemistry
DOI 10.1074/jbc.r112.431916
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.r112.431916

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 80

  1. Guengerich, 2008, Cytochrome P450 and chemical toxicology, Chem. Res. Toxicol, 21, 70, 10.1021/tx700079z · DOI · Paper page
  2. Miller, 2011, Early steps in steroidogenesis: intracellular cholesterol trafficking, J. Lipid Res, 52, 2111, 10.1194/jlr.R016675 · DOI · Paper page
  3. Tajima, 2001, Heterozygous mutation in the cholesterol side chain cleavage enzyme (P450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency, J. Clin. Endocrinol. Metab, 86, 3820, 10.1210/jcem.86.8.7748 · DOI · Paper page
  4. Katsumata, 2002, Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans, J. Clin. Endocrinol. Metab, 87, 3808, 10.1210/jcem.87.8.8763 · DOI · Paper page
  5. Hiort, 2005, Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46,XY sex reversal, and severe adrenal failure, J. Clin. Endocrinol. Metab, 90, 538, 10.1210/jc.2004-1059 · DOI · Paper page
  6. Kim, 2008, Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc, J. Clin. Endocrinol. Metab, 93, 696, 10.1210/jc.2007-2330 · DOI · Paper page
  7. al Kandari, 2006, Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46,XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum, J. Clin. Endocrinol. Metab, 91, 2821, 10.1210/jc.2005-2230 · DOI · Paper page
  8. Sahakitrungruang, 2011, Partial defect in the cholesterol side-chain cleavage enzyme P450scc (CYP11A1) resembling nonclassic congenital lipoid adrenal hyperplasia, J. Clin. Endocrinol. Metab, 96, 792, 10.1210/jc.2010-1828 · DOI · Paper page
  9. White, 1986, Steroid 21-hydroxylase deficiency and the major histocompatibility complex, Hum. Immunol, 15, 404, 10.1016/0198-8859(86)90018-2 · DOI
  10. Zhao, 2012, Three-dimensional structure of steroid 21-hydroxylase (cytochrome P450 21A2) with two substrates reveals locations of disease-associated variants, J. Biol. Chem, 287, 10613, 10.1074/jbc.M111.323501 · DOI
  11. DeVore, 2012, Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001, Nature, 482, 116, 10.1038/nature10743 · DOI · Paper page
  12. Auchus, 1998, Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer, J. Biol. Chem, 273, 3158, 10.1074/jbc.273.6.3158 · DOI · Paper page
  13. Yap, 2008, Targeting CYP17: established and novel approaches in prostate cancer, Curr. Opin. Pharmacol, 8, 449, 10.1016/j.coph.2008.06.004 · DOI
  14. Vasaitis, 2011, CYP17 inhibitors for prostate cancer therapy, J. Steroid Biochem. Mol. Biol, 125, 23, 10.1016/j.jsbmb.2010.11.005 · DOI
  15. Peter, 1999, Disorders of the aldosterone synthase and steroid 11β-hydroxylase deficiencies, Horm. Res, 51, 211
  16. Hampf, 2001, Unequal crossing-over between aldosterone synthase and 11β-hydroxylase genes causes congenital adrenal hyperplasia, J. Clin. Endocrinol. Metab, 86, 4445
  17. Parajes, 2010, Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11β-hydroxylase deficiency, J. Clin. Endocrinol. Metab, 95, 779, 10.1210/jc.2009-0651 · DOI
  18. Nguyen, 2010, Five novel mutations in CYP11B2 gene detected in patients with aldosterone synthase deficiency type I: functional characterization and structural analyses, Mol. Genet. Metab, 100, 357, 10.1016/j.ymgme.2010.04.016 · DOI
  19. Simpson, 2011, Obesity, aromatase and breast cancer, Expert Rev. Endocrinol. Metab, 6, 383, 10.1586/eem.11.35 · DOI
  20. Jones, 2007, Recognizing rare disorders: aromatase deficiency, Nat. Clin. Pract. Endocrinol. Metab, 3, 414, 10.1038/ncpendmet0477 · DOI
  21. Buzdar, 2002, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane, Cancer, 95, 2006, 10.1002/cncr.10908 · DOI · Paper page
  22. Charlesworth, 2009, Toward the identification of causal genes in complex diseases: a gene-centric joint test of significance combining genomic and transcriptomic data, BMC Proc, 3, S92, 10.1186/1753-6561-3-S7-S92 · DOI
  23. Pullinger, 2002, Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype, J. Clin. Invest, 110, 109, 10.1172/JCI0215387 · DOI · Paper page
  24. Pikuleva, 2008, Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering, Expert Opin. Drug Metab. Toxicol, 4, 1403, 10.1517/17425255.4.11.1403 · DOI
  25. Lorbek, 2012, Cytochrome P450s in the synthesis of cholesterol and bile acids–from mouse models to human diseases, FEBS J, 279, 1516, 10.1111/j.1742-4658.2011.08432.x · DOI
  26. Cali, 1991, Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis, J. Biol. Chem, 266, 7774, 10.1016/S0021-9258(20)89517-9 · DOI · Paper page
  27. Cali, 1991, Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis, J. Biol. Chem, 266, 7779, 10.1016/S0021-9258(20)89518-0 · DOI · Paper page
  28. Gallus, 2006, Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene, Neurol. Sci, 27, 143, 10.1007/s10072-006-0618-7 · DOI
  29. Lorincz, 2005, Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized, Arch. Neurol, 62, 1459, 10.1001/archneur.62.9.1459 · DOI
  30. Pilo-de-la-Fuente, 2011, Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey, Eur. J. Neurol, 18, 1203, 10.1111/j.1468-1331.2011.03439.x · DOI
  31. Gallus, 2010, Four novel CYP27A1 mutations in seven Italian patients with CTX, Eur. J. Neurol, 17, 1259, 10.1111/j.1468-1331.2010.03002.x · DOI
  32. Björkhem, 1997, Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro, J. Biol. Chem, 272, 30178, 10.1074/jbc.272.48.30178 · DOI · Paper page
  33. Lund, 1999, cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain, Proc. Natl. Acad. Sci. U.S.A, 96, 7238, 10.1073/pnas.96.13.7238 · DOI · Paper page
  34. Kotti, 2006, Brain cholesterol turnover required for geranylgeraniol production and learning in mice, Proc. Natl. Acad. Sci. U.S.A, 103, 3869, 10.1073/pnas.0600316103 · DOI · Paper page
  35. Famer, 2007, Regulation of α- and β-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the α-secretase pathway, Biochem. Biophys. Res. Commun, 359, 46, 10.1016/j.bbrc.2007.05.033 · DOI
  36. Brown, 2004, Differential expression of cholesterol hydroxylases in Alzheimer's disease, J. Biol. Chem, 279, 34674, 10.1074/jbc.M402324200 · DOI · Paper page
  37. Fourgeux, 2009, Primary open-angle glaucoma: association with cholesterol 24S-hydroxylase (CYP46A1) gene polymorphism and plasma 24-hydroxycholesterol levels, Invest. Ophthalmol. Vis. Sci, 50, 5712, 10.1167/iovs.09-3655 · DOI
  38. Mossböck, 2011, Role of cholesterol 24S-hydroxylase gene polymorphism (rs754203) in primary open angle glaucoma, Mol. Vis, 17, 616
  39. Stapleton, 1995, A novel cytochrome P450 expressed primarily in brain, J. Biol. Chem, 270, 29739, 10.1074/jbc.270.50.29739 · DOI
  40. Rose, 1997, Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7α-hydroxy dehydroepiandrosterone and 7α-hydroxypregnenolone, Proc. Natl. Acad. Sci. U.S.A, 94, 4925, 10.1073/pnas.94.10.4925 · DOI
  41. Schwarz, 1997, Identification and characterization of a mouse oxysterol 7α-hydroxylase cDNA, J. Biol. Chem, 272, 23995, 10.1074/jbc.272.38.23995 · DOI
  42. Martin, 1997, 7α-Hydroxylation of 27-hydroxycholesterol: biologic role in the regulation of cholesterol synthesis, J. Lipid Res, 38, 1053, 10.1016/S0022-2275(20)37229-1 · DOI
  43. Li-Hawkins, 2000, Expression cloning of an oxysterol 7α-hydroxylase selective for 24-hydroxycholesterol, J. Biol. Chem, 275, 16543, 10.1074/jbc.M001810200 · DOI
  44. Schwarz, 2001, Alternate pathways of bile acid synthesis in the cholesterol 7α-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding, J. Lipid Res, 42, 1594, 10.1016/S0022-2275(20)32213-6 · DOI
  45. Rose, 2001, Neurosteroid hydroxylase CYP7B. Vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation, J. Biol. Chem, 276, 23937, 10.1074/jbc.M011564200 · DOI
  46. Weihua, 2002, An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth, Proc. Natl. Acad. Sci. U.S.A, 99, 13589, 10.1073/pnas.162477299 · DOI · Paper page
  47. Omoto, 2005, Early onset of puberty and early ovarian failure in CYP7B1 knockout mice, Proc. Natl. Acad. Sci. U.S.A, 102, 2814, 10.1073/pnas.0500198102 · DOI
  48. Tsaousidou, 2008, Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration, Am. J. Hum. Genet, 82, 510, 10.1016/j.ajhg.2007.10.001 · DOI
  49. Ueki, 2008, Neonatal cholestatic liver disease in an Asian patient with a homozygous mutation in the oxysterol 7α-hydroxylase gene, J. Pediatr. Gastroenterol. Nutr, 46, 465, 10.1097/MPG.0b013e31815a9911 · DOI
  50. Biancheri, 2009, White matter lesions in spastic paraplegia with mutations in SPG5/CYP7B1, Neuromuscul. Disord, 19, 62, 10.1016/j.nmd.2008.10.009 · DOI
  51. Schüle, 2009, Analysis of CYP7B1 in non-consanguineous cases of hereditary spastic paraplegia, Neurogenetics, 10, 97, 10.1007/s10048-008-0158-9 · DOI
  52. Goizet, 2009, CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5, Brain, 132, 1589, 10.1093/brain/awp073 · DOI
  53. Stiles, 2009, CYP7B1: one cytochrome P450, two human genetic diseases, and multiple physiological functions, J. Biol. Chem, 284, 28485, 10.1074/jbc.R109.042168 · DOI
  54. Cheng, 2003, De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxylase, J. Biol. Chem, 278, 38084, 10.1074/jbc.M307028200 · DOI · Paper page
  55. Choudhary, 2005, Expression patterns of mouse and human CYP orthologs (families 1–4) during development and in different adult tissues, Arch. Biochem. Biophys, 436, 50, 10.1016/j.abb.2005.02.001 · DOI · Paper page
  56. Cheng, 2004, Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase, Proc. Natl. Acad. Sci. U.S.A, 101, 7711, 10.1073/pnas.0402490101 · DOI · Paper page
  57. Schuster, 2011, Cytochromes P450 are essential players in the vitamin D signaling system, Biochim. Biophys. Acta, 1814, 186, 10.1016/j.bbapap.2010.06.022 · DOI · Paper page
  58. Zhu, 2012, Vitamin D 25-hydroxylase–four decades of searching, are we there yet?, Arch. Biochem. Biophys, 523, 30, 10.1016/j.abb.2012.01.013 · DOI
  59. Dong, 2004, Vitamin D 25-hydroxylase deficiency, Mol. Genet. Metab, 83, 197, 10.1016/j.ymgme.2004.07.006 · DOI
  60. Levine, 2007, Tropical rickets in Nigeria: mutation of the CYP2R1 gene encoding vitamin D 25-hydroxylase as a cause of vitamin D dependent rickets, Bone, 40, S60, 10.1016/j.bone.2007.04.079 · DOI
  61. Al Mutair, 2012, Mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family with severe vitamin D deficiency, J. Clin. Endocrinol. Metab, 97, E2022, 10.1210/jc.2012-1340 · DOI
  62. Strushkevich, 2008, Structural analysis of CYP2R1 in complex with vitamin D3, J. Mol. Biol, 380, 95, 10.1016/j.jmb.2008.03.065 · DOI
  63. Adams, 2012, Extrarenal expression of the 25-hydroxyvitamin D 1-hydroxylase, Arch. Biochem. Biophys, 523, 95, 10.1016/j.abb.2012.02.016 · DOI · Paper page
  64. Akiba, 1980, Localization of 25-hydroxyvitamin D3 1α-hydroxylase activity in the mammalian kidney, Biochem. Biophys. Res. Commun, 94, 313, 10.1016/S0006-291X(80)80222-1 · DOI
  65. Fu, 1997, Cloning of human 25-hydroxyvitamin D 1α-hydroxylase and mutations causing vitamin D-dependent rickets type 1, Mol. Endocrinol, 11, 1961
  66. Kitanaka, 1998, Inactivating mutations in the 25-hydroxyvitamin D3 1α-hydroxylase gene in patients with pseudovitamin D-deficiency rickets, N. Engl. J. Med, 338, 653, 10.1056/NEJM199803053381004 · DOI · Paper page
  67. Cui, 2012, Novel mutations of CYP27B1 gene lead to reduced activity of 1α-hydroxylase in Chinese patients, Bone, 51, 563, 10.1016/j.bone.2012.05.006 · DOI
  68. Kitanaka, 1999, No enzyme activity of 25-hydroxyvitamin D3 1α-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation, J. Clin. Endocrinol. Metab, 84, 4111
  69. Wang, 1998, Genetics of vitamin D 1α-hydroxylase deficiency in 17 families, Am. J. Hum. Genet, 63, 1694, 10.1086/302156 · DOI
  70. Wang, 2002, Novel gene mutations in patients with 1α-hydroxylase deficiency that confer partial enzyme activity in vitro, J. Clin. Endocrinol. Metab, 87, 2424
  71. Schlingmann, 2011, Mutations in CYP24A1 and idiopathic infantile hypercalcemia, N. Engl. J. Med, 365, 410, 10.1056/NEJMoa1103864 · DOI · Paper page
  72. Dauber, 2012, Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia, J. Clin. Endocrinol. Metab, 97, E268, 10.1210/jc.2011-1972 · DOI
  73. Tebben, 2012, Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy, J. Clin. Endocrinol. Metab, 97, E423, 10.1210/jc.2011-1935 · DOI
  74. Streeten, 2011, CYP24A1 mutations in idiopathic infantile hypercalcemia, N. Engl. J. Med, 365, 1741, 10.1056/NEJMc1110226 · DOI
  75. Annalora, 2010, Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism, J. Mol. Biol, 396, 441, 10.1016/j.jmb.2009.11.057 · DOI
  76. Gainer, 2005, Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension, Circulation, 111, 63, 10.1161/01.CIR.0000151309.82473.59 · DOI
  77. Capdevila, 2007, Regulation of ion transport and blood pressure by cytochrome P450 monooxygenases, Curr. Opin. Nephrol. Hypertens, 16, 465, 10.1097/MNH.0b013e32827ab48c · DOI
  78. Capdevila, 2007, Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension, Kidney Int, 72, 683, 10.1038/sj.ki.5002394 · DOI
  79. Gainer, 2008, Association of a CYP4A11 variant and blood pressure in black men, J. Am. Soc. Nephrol, 19, 1606, 10.1681/ASN.2008010063 · DOI
  80. Hiratsuka, 2006, Genetic polymorphisms and haplotype structures of the CYP4A22 gene in a Japanese population, Mutat. Res, 599, 98, 10.1016/j.mrfmmm.2006.02.008 · DOI

Cited by

See all 101

Metadata

Authors
Pikuleva, I. A., & Waterman, M. R.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2013-06
Volume
288
Issue
24
Pages
17091-17098
ISSN
0021-9258
DOI
10.1074/jbc.r112.431916
Cited by
101
References
12
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.